Browsing Tag
umedaptanib pegol
1 post
RIBOMIC completes patient enrollment in early phase II study of umedaptanib pegol for Achondroplasia
RIBOMIC Inc., a Tokyo-based leader in aptamer therapeutics, has reported significant progress in its early phase II study…